Freudenberg Medical Business Group Acquires Majority Stake in Hemoteq

The Freudenberg Medical Business Group has acquired a 75% stake in Hemoteq AG, a Würselen, Germany-based leader in coating technologies and services for medical technology products.

Freudenberg Medical therefore acquires the shares of the current shareholders Earlybird Venture Capital and Pinova Capital while the remaining 25% of the shares in the company will continue to be held by its founders, Dr. Michael Hoffmann and Roland Horres. Dr. Max Gisbert Kley, President Freudenberg Medical Europe will take the chair of the supervisory board.

Hemoteq AG provides services from the development and approval of medical devices through to series production. The acquisition will allow Freudenberg Group, a global manufacturer of special components and systems for the medical technology and pharmaceutical industries, to reinforce its technological competence in the medical sector.



Join the discussion